A small percentage of patients with epilepsy are caused by genetic mutations, such as tuberous sclerosis, Dravet syndrome, nocturnal frontal lobe epilepsy, familial neonatal convulsions, and so on. These diseases, when clarified by genetic testing, can be treated in a targeted manner, while avoiding the use of some drugs. Tuberous sclerosis can be tried with mTOR blockers, such as fenitrol and rapamycin. Carbamazepine or oxcarbazepine is preferred for nocturnal frontal lobe epilepsy. However, oxcarbazepine and carbamazepine are absolutely contraindicated in Drave’s syndrome. This Drave syndrome is an epilepsy syndrome caused by mutations in SCN1A and, in a few cases, mutations in SN1B, 2A, 9A, GABRG2 and other genes. It manifests as extreme heat sensitivity with convulsions at the slightest fever, which can be accompanied by myoclonus, atypical aphasia and partial seizures. Milder cases can have no cognitive decompensation, and severe cases have severe intellectual regression. Even some relatively mild febrile convulsion families have mutations in SCN1A, and doctors do not have the awareness to screen patients for the gene, resulting in random prescription of some kama and oca, which leads to aggravation of the patient’s condition. In some cases, the doctor was still obsessed with increasing the dose of Oka, which led to the patient’s seizure status. One of my patients suffered such a misfortune, and the more healing he got in the so-called big hospitals, the worse he got! Finally, in the end, once again emphasize. Febrile convulsions should not be disregarded, there is genetic best to check the genes. Once the SCN1A mutation, oxcarbazepine, carbamazepine, lamotrigine, phenytoin sodium caution, if it is typical Dravet syndrome, the above drugs are absolutely contraindicated, with is to harm life!